Form 4: HilleVax Director Aditya Kohli Sells Shares Under 10b5-1 Trading Plan

Director Aditya Kohli of HilleVax, Inc. executed sales of common stock totaling 18,000 shares between May 20 and May 22, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Aditya Kohli, a director of HilleVax, Inc., sold 18,000 shares of common stock over three days.
• The sales occurred on May 20, 21, and 22, 2024.
• Each day, 6,000 shares were sold.
• The sales were executed under a Rule 10b5-1 trading plan adopted on October 12, 2023.
• The weighted average sale prices were $15.4482 on May 20, $14.205 on May 21, and $14.7287 on May 22.
• Following these transactions, Kohli directly owns 764,878 shares of HilleVax common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing simply reports stock sales under a pre-arranged plan, which doesn't inherently indicate positive or negative sentiment about the company's prospects.

Positives

• The sales were executed under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.

Risks

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors.

Industry Context

Insider trading activity is always closely watched in the biotech industry, especially for companies like HilleVax that are in the development stage. Monitoring insider transactions provides insights into management's perspective on the company's valuation and future prospects.

Comparison to Industry Standards

• It's common for directors and officers of publicly traded companies, including those in the biotech sector like HilleVax, to utilize 10b5-1 trading plans to sell shares.
• Companies like Moderna, BioNTech, and Novavax also see regular insider trading activity, often under similar pre-arranged plans.
• The volume and frequency of these sales are generally compared against historical insider trading patterns and industry benchmarks to assess their significance.

Stakeholder Impact

• The stock sales could have a minor impact on shareholder sentiment, depending on how the market interprets the transactions.

Key Dates